An unsuccessful embryo transfer can be emotionally difficult. After several failed transfers, many patients understandably start looking for a hidden explanation: the embryo, the uterine lining, an immune problem, blood clotting, sperm DNA or the timing of implantation.
However, one or even several unsuccessful transfers do not automatically prove the existence of a separate disease called recurrent implantation failure (RIF).
The concept itself remains challenging because the probability that an embryo will implant varies substantially according to maternal age, embryo ploidy, embryo stage, treatment history and other clinical factors.
ESHRE therefore moved away from defining RIF simply by a fixed number of failed transfers. It describes RIF as a situation in which embryos considered viable have failed to produce a positive pregnancy test often enough in a specific patient that additional investigation or intervention becomes reasonable. An individualised cumulative implantation probability is preferred over a one-size-fits-all number.
ASRM's 2026 committee opinion similarly recommends beginning with a detailed review of medical and reproductive history, imaging and the previous IVF cycles. If no clear correctable cause emerges, extensive additional testing is not considered routinely necessary.
What is embryo implantation?
Implantation is the process through which the developing blastocyst attaches to and penetrates the endometrium.
Clinically, implantation is initially detected by hCG and later by evidence of an intrauterine pregnancy on ultrasound.
When pregnancy does not occur after transfer, it is often impossible to identify one single point at which treatment “failed.”
Potential contributors may involve:
The embryo.
The uterine cavity.
The endometrium.
Embryo-transfer technique.
Treatment-cycle factors.
Or no identifiable abnormality at all.
Does one failed embryo transfer mean RIF?
No.
Even an apparently high-quality embryo never has a 100% implantation probability.
Morphologically good embryos can also be chromosomally abnormal, particularly as oocyte age increases.
A single failed transfer can therefore fall within the expected probability of IVF treatment and does not automatically justify extensive additional testing.
How many failed transfers define recurrent implantation failure?
There is no universally appropriate fixed number.
Historically, definitions have included:
Two failed transfers.
Three failed transfers.
Failure after a predefined number of “good-quality” embryos.
The problem is that these definitions treat very different patients as though their baseline implantation probability were identical.
ESHRE recommends considering each patient's cumulative predicted implantation chance and suggests that further evaluation may become reasonable when that expected cumulative probability exceeds approximately 60% without implantation.
First step: review the previous IVF cycles
Before ordering new tests, existing information should be reviewed carefully.
Relevant details include:
Female age at egg retrieval.
Number of mature oocytes.
Fertilization method.
Embryo development.
Embryo stage at transfer.
Embryo morphology.
Whether PGT was performed.
Endometrial thickness.
Ease or difficulty of transfer.
Previous uterine imaging.
Endometrial preparation.
Relevant hormone measurements.
Remaining frozen embryos.
Sometimes this review identifies a practical issue without any need for a broad “RIF panel.”
Embryo-related causes
The embryo itself is one of the most important determinants of implantation.
Chromosomal abnormalities
Embryo aneuploidy increases with advancing oocyte age.
Repeated transfer failure with untested embryos therefore does not necessarily indicate an endometrial problem.
Some failed transfers may simply reflect the probability of transferring chromosomally abnormal embryos.
Does PGT-A treat recurrent implantation failure?
Not by itself.
PGT-A can provide information about embryo chromosome copy number and may help embryo-selection decisions in selected situations.
However, ASRM's 2026 review states that there is currently no evidence that PGT-A increases live-birth rates specifically in patients with RIF.
It may be discussed with patients who have experienced RIF with untested embryos as part of shared decision-making, but it should not be presented as a guaranteed treatment.
See PGT Embryo Testing.
Uterine-cavity factors
Structural abnormalities within the uterine cavity can affect implantation.
Possible findings include:
Endometrial polyps.
Submucosal fibroids.
Intrauterine adhesions.
Certain uterine anomalies.
Hydrosalpinx.
ASRM considers uterine-cavity assessment with sonohysterography, hysteroscopy or three-dimensional ultrasound reasonable when RIF is suspected, particularly if the cavity has not been adequately evaluated.
Does every patient need hysteroscopy?
No.
Hysteroscopy can be especially useful when imaging or history suggests:
A polyp.
A cavity-distorting fibroid.
Adhesions.
Another intracavitary lesion.
ASRM considers it reasonable to offer hysteroscopy for cavity evaluation and removal of endometrial polyps and submucosal fibroids, but this does not mean routine hysteroscopy is necessary after every unsuccessful transfer.
See Diagnostic Hysteroscopy After IVF Failure.
What about hydrosalpinx?
Hydrosalpinx is a fluid-filled, dilated fallopian tube.
In some patients, fluid can communicate with the uterine cavity and adversely affect implantation.
A previously unrecognised hydrosalpinx should therefore be considered during structural reassessment when the history or imaging suggests tubal disease.
Endometrial factors
Implantation requires an appropriate endometrium at an appropriate time.
However, “endometrial quality” cannot be reduced to one measurement.
Thin endometrium
Persistent thin endometrium may prompt review of:
Estradiol exposure.
Endometrial-preparation duration.
Previous uterine procedures.
Possible adhesions.
ESHRE recommends reassessing endometrial thickness and reviewing the preparation regimen; hysteroscopy can be considered when persistent thin endometrium raises concern for adhesions or Asherman syndrome.
Do ERA and endometrial-receptivity tests help?
These tests have been heavily marketed to patients with repeated unsuccessful transfers.
The principle is to analyse endometrial gene expression and adjust progesterone exposure according to a proposed personalised implantation window.
However, available studies have not demonstrated a consistent live-birth benefit from routine use.
ASRM's 2026 review includes studies showing no benefit and some reporting poorer cumulative outcomes in tested groups, so routine receptivity testing should not automatically follow repeated transfer failure.
See Endometrial Receptivity Testing.
Chronic endometritis
Chronic endometritis is persistent low-grade inflammation of the endometrium and has been associated in some studies with poorer reproductive outcomes.
Evaluation can include:
Endometrial biopsy.
CD138 immunohistochemistry.
Hysteroscopic findings in selected situations.
A major limitation is the absence of universally agreed diagnostic thresholds.
ASRM therefore considers testing and treatment something that may be discussed in selected patients, while recognising that evidence remains inconclusive for routine use.
Endometriosis and adenomyosis
Some forms of endometriosis and adenomyosis may contribute to lower implantation probability.
However, their presence does not mean that every patient should automatically receive prolonged suppression before embryo transfer.
ASRM notes that GnRH agonist or aromatase-inhibitor suppression can be considered in selected patients, but evidence for improving live birth remains inconclusive and routine treatment cannot be recommended.
Should both partners have karyotyping?
Parental karyotyping may be considered in selected patients to look for structural chromosomal rearrangements such as balanced translocations.
ASRM states that parental karyotype testing may be considered in RIF, with genetic counselling and possible PGT-SR if an abnormal structural rearrangement is identified.
It is not automatically required after one unsuccessful embryo transfer.
Is sperm DNA fragmentation testing necessary?
Not routinely for RIF.
Although sperm DNA fragmentation has received substantial attention in infertility and pregnancy-loss research, evidence linking it specifically to recurrent implantation failure remains limited.
ASRM 2026 concludes that evidence is currently insufficient to recommend routine sperm DNA fragmentation testing in the RIF population.
See Sperm DNA Fragmentation Testing.
What about immune testing and NK cells?
Many fertility add-on panels include:
Natural killer cells.
Cytokine profiles.
HLA testing.
Broad immune panels.
A plausible biological theory, however, does not prove that a test identifies a treatable problem or that treating the result improves live birth.
Broad immune testing should therefore not automatically follow repeated transfer failure.
Do intralipids or IVIG help?
Immune therapies such as IVIG and intralipid infusions are offered in some settings.
They have not become established standard treatments for RIF.
ESHRE and ASRM emphasise restricting investigations and interventions to those with a clear biological and clinical rationale rather than routinely adding unproven treatments after unsuccessful transfers.
What about G-CSF?
G-CSF has been studied in several reproductive settings, including thin endometrium and implantation failure.
Available studies remain inconsistent.
It therefore should not be presented as an established routine treatment for RIF.
Does endometrial scratching work?
Endometrial scratching was proposed as a way of creating a local injury that might stimulate a favourable implantation response.
Larger studies have not demonstrated sufficient benefit to justify routine use.
A previous failed transfer alone is therefore not a reason to automatically perform scratching.
Does heparin or Lovenox improve implantation?
Anticoagulants are appropriate when a patient has a specific medical indication.
That is different from prescribing them solely because embryo transfers have failed.
In patients without antiphospholipid antibody syndrome, ASRM notes that studies of heparin and low-molecular-weight heparin have produced conflicting results without clear evidence of benefit.
Is aspirin necessary?
Not routinely.
Aspirin should similarly be based on a specific clinical indication rather than added automatically because of RIF.
What about intrauterine PRP?
Intrauterine platelet-rich plasma has been studied for thin endometrium and recurrent transfer failure.
Some small studies have reported favourable findings, but current evidence is not sufficiently robust to consider PRP an established routine RIF treatment.
Patients should understand this uncertainty before using it as an add-on.
Should the embryo-transfer protocol be changed?
Sometimes, but only after reviewing what might need correction.
The team may examine:
Natural versus programmed endometrial preparation.
Progesterone timing and exposure.
Transfer difficulty.
Ultrasound guidance.
Embryo stage.
Catheter choice.
Technical problems during transfer.
Changing multiple variables simultaneously makes it difficult to know which change actually mattered.
Is RIF the same as recurrent miscarriage?
No.
Implantation failure
A transferred embryo does not result in the clinical milestone used to define implantation.
Recurrent pregnancy loss
Pregnancy occurs and is subsequently lost.
The evaluations overlap in certain areas, but the conditions are not interchangeable.
A test useful in recurrent pregnancy loss may have insufficient evidence in RIF.
See Recurrent Miscarriage: Advanced Testing and IVF Options.
A practical approach after repeated failed transfers
A structured review can proceed in stages.
1. Confirm whether the pattern truly suggests RIF
Consider age, number of transfers and whether embryos were euploid or untested.
2. Review embryo history
Examine embryo numbers, development, stage and laboratory history.
3. Review transfer technique
Especially if previous transfers were difficult.
4. Reassess the uterus
When uterine-cavity evaluation is incomplete or structural pathology is suspected.
5. Consider the fallopian tubes
Particularly possible hydrosalpinx.
6. Review the endometrial protocol
Including thickness and progesterone exposure.
7. Add targeted specialised tests only when clinically justified
For example, parental karyotyping or chronic-endometritis assessment in selected patients.
8. Avoid automatically stacking add-ons
Every proposed test should answer two questions:
What abnormality are we looking for?
And if the test is abnormal, is there an intervention proven to improve live birth?
Can pregnancy still occur after several failed transfers?
Yes.
Previous failed transfers do not mean that a future transfer cannot succeed.
ASRM's 2026 opinion makes an important point: when detailed review does not identify a clear correctable abnormality, extensive additional testing may be unnecessary, and proceeding with further embryo transfer can be reasonable because many patients ultimately achieve pregnancy.
When is a second opinion useful?
A second review can be particularly useful when:
Several transfers have failed.
The reason for the current treatment plan is unclear.
A broad immune panel has been recommended.
ERA, IVIG, intralipid, PRP or G-CSF is presented as a guaranteed solution.
Uterine or tubal pathology has not been properly reviewed.
There is uncertainty about embryo quality or PGT.
Evidence-based treatment and experimental add-ons have not been clearly distinguished.
Conclusion
Recurrent implantation failure is not a simple diagnosis defined by one fixed number of unsuccessful embryo transfers.
A useful evaluation begins with the patient's age, embryo history, previous IVF cycles, transfer technique, uterine cavity, fallopian tubes and endometrial preparation, followed by targeted testing when the review provides a clinical reason.
Some interventions can be important when a defined abnormality is found, such as treatment of an endometrial polyp, submucosal fibroid or hydrosalpinx.
Other frequently marketed tests and add-ons—including routine receptivity testing, scratching, broad immune therapies, G-CSF or anticoagulation without a specific indication—do not currently have sufficient evidence to become automatic treatment for every patient with repeated failed transfers. ASRM's 2026 guidance specifically advises against unnecessary extensive testing when no correctable factor is found.
If you have experienced several unsuccessful embryo transfers, Safemedigo can coordinate review of your previous IVF cycles, embryo reports, imaging and laboratory results with the fertility team to identify what genuinely needs reassessment before another attempt. Contact Safemedigo on WhatsApp.
Frequently Asked Questions
How many failed embryo transfers are needed before RIF is diagnosed?
There is no universal fixed number. Modern guidance favours an individual assessment based on age, embryo characteristics and the cumulative expected probability of implantation.
Do I need hysteroscopy after several failed transfers?
Not everyone does. It becomes more relevant when the uterine cavity has not been adequately assessed or when a polyp, fibroid, adhesion or other structural abnormality is suspected.
Is ERA necessary after failed embryo transfers?
No. Current evidence does not support routine endometrial-receptivity testing for every patient with suspected RIF, and consistent improvement in live birth has not been demonstrated.
Does PGT-A improve success after recurrent implantation failure?
PGT-A may provide embryo-ploidy information in selected cases, but there is currently no evidence that it specifically increases live-birth rates in patients with RIF.
Can natural pregnancy occur after repeated IVF transfer failure?
Possibly, depending on the original cause of infertility, age, tubal status, semen factors and other circumstances. Previous IVF failure alone does not make natural conception impossible for every patient.
